SCHEMBL24329373

SCHEMBL24329373

COc1ccc2sc(NC(=O)c3ccn(C)n3)nc2c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 13/20 0.63
▸ RAB9A P51151 12/20 0.63
▸ SMN1; SMN2 Q16637 7/20 0.63
▸ DYRK1A Q13627 2/20 0.63
▸ TP53 P04637 4/20 0.59
▸ PKM P14618 1/20 0.59
▸ APOBEC3A P31941 1/20 0.59
▸ APOBEC3G Q9HC16 1/20 0.59
▸ SCD O00767 7/20 0.57
▸ MEN1 O00255 6/20 0.57
▸ KMT2A Q03164 6/20 0.57
▸ ALDH1A1 P00352 1/20 0.56
▸ ALOX15 P16050 1/20 0.56
▸ MAPK1 P28482 1/20 0.56
▸ MAPT P10636 2/20 0.56
▸ HTT P42858 2/20 0.53
▸ USP2 O75604 1/20 0.53
▸ POLB P06746 1/20 0.53
▸ CSNK2A2 P19784 1/20 0.52
▸ CSNK2B P67870 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24329378 0.91 NPC1 (0.66) NPC1RAB9ASMN1; SMN2DYRK1ATP53
SCHEMBL26658231 0.85 DYRK1A (0.61) NPC1RAB9ASMN1; SMN2DYRK1ATP53
SCHEMBL26658545 0.81 NPC1 (0.67) NPC1RAB9ASMN1; SMN2DYRK1ATP53
SCHEMBL31061590 0.78 DYRK1A (1.00) NPC1RAB9ASMN1; SMN2DYRK1ATP53
SCHEMBL26884255 0.78 KDM4E (0.48) NPC1RAB9ASMN1; SMN2DYRK1APKM
SCHEMBL26886465 0.78 HPGD (0.52) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL14807738 0.77 SCD (0.74) NPC1RAB9ASMN1; SMN2DYRK1ATP53
SCHEMBL26884209 0.76 NPC1 (0.51) NPC1RAB9ASMN1; SMN2TP53PKM
SCHEMBL24329679 0.76 MEN1 (0.62) NPC1RAB9ASMN1; SMN2TP53MEN1
SCHEMBL26884262 0.76 DYRK1A (0.63) NPC1RAB9ASMN1; SMN2DYRK1ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230382903-A1 SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF USE THEREOF CARTHRONIX INC (US) 2023-11-30 — — US disclosed
US-20230382903-A1 SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF USE THEREOF CARTHRONIX INC (US) 2023-11-30 — — US disclosed
WO-2022082071-A1 SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF US THEREOF CARTHRONIX, INC. (US) 2022-04-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230382903-A1 SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF USE THEREOF STAT1, STAT3, STAT6 NPC1 2133/4885RAB9A 3504/4885SMN1; SMN2 4696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback